Latest Incyte Corp (INCY) Headlines
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Positive Data on Novartis' Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 3:50PM CDT
Novartis announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Cancer Immunotherapy Race Stays Unpredictable
Amy Ho, The Motley Fool - Motley Fool - Fri Mar 07, 10:00AM CST
Cancer immunotherapy is a very hot field, and Bristol-Myers Squibb certainly took note, reallocating resources late last year to focus on the field, selling off its diabetes arm to AstraZeneca and ending new research in diabetes, hepatitis C and...
'Mad Money' Lightning Round: SunEdison Is Way Too Hot
at The Street - Fri Mar 07, 5:00AM CST
Cramer is avoiding GT Advanced Technologies and Incyte but wants Whole Foods for the long term.
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Business Wire - Fri Mar 07, 12:15AM CST
--Ruxolitinib is the first selective JAK1/JAK2 inhibitor to demonstrate efficacy in a Phase III trial for treating polycythemia vera
Jim Cramer's 'Mad Money' Recap: How to Value a Stock
at The Street - Thu Mar 06, 7:08PM CST
There are many ways to do so, and sticking to just one will cost you money, Cramer warns.
Incyte to Present at Upcoming Investor Conferences
Business Wire - Tue Feb 18, 3:10PM CST
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March:
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 4:05PM CST
Stock market correction, it's like we hardly even knew you! After dipping more than 100 points below its all-time closing high, the broad-based S&P 500 has now galloped higher in four of the past five trading sessions and is once again within...
The Hidden Gems in Gilead Sciences' Pipeline
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 1:30PM CST
When most biotech investors think about Gilead Sciences , they usually think of the company's portfolio of antiviral drugs and its newly approved potential blockbuster hepatitis C treatment, Sovaldi. Gilead's antiviral portfolio,...
Wider-than-Expected Q4 Loss at Incyte - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 12:10PM CST
Incyte reported a loss of 15 cents per share in the fourth quarter of 2013 wider than the Zacks Consensus Estimate of a loss of 9 cents.
Incyte Q4 swings to a loss
at Investor's Business Daily - Wed Feb 12, 5:43PM CST
The biotech reported a loss of 15 cents per share vs. a gain of 14 cents per share in the year-ago quarter. Analysts expected an 11-cent loss. Revenue fell 14.7% to $97.07 mil, falling short of views for $97.25 mil. Incyte (INCY) revenues from its...
Incyte's Q4 Loss Widens Despite Improved Jakafi Sales
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 12, 12:38PM CST
Oncology and inflammation-focused biopharmaceutical company Incyte reported its fourth-quarter results before the opening bell today. Incyte's results point toward growing sales of its lead drug, but also growing losses. For the quarter,...
Why Incyte (INCY) Is Up Today
at The Street - Wed Feb 12, 11:52AM CST
Incyte (INCY) rises to a nearly 14-year high of $69.98 as of 12:15 p.m. on Wednesday after the pharmaceutical company announced its fourth-quarter and full-year results. For the quarter and full year, both of which ended on Dec. 31, 2013, net product...
Today’s Top Biotech Stories: The Medicines Company, DaVita HealthCare Partners, and Incyte
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 7:45AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs
Business Wire - Wed Feb 12, 6:00AM CST
--Net product revenue guidance for 2014 in the range of $315 million to $335 million, reflecting continued growth in underlying demand
Merck Falling Earnings Hide Hidden Potential
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Sat Feb 08, 6:00AM CST
In this segment from Market Checkup , Motley Fool's health-care focused investing show, analysts David Williamson and Max Macaluso look at Merck's recent quarterly results. The Big Pharma posted declining revenue and net income, missing analyst...
5 Stocks Moving The Health Care Sector Upward
at The Street - Thu Feb 06, 11:03AM CST
TheStreet highlights 5 stocks pushing the health care sector higher today.
Merck soars on cancer deal
at Investor's Business Daily - Wed Feb 05, 5:56PM CST
The pharmaceutical giant's Q4 EPS rose 6% to 88 cents, in line with views. Sales fell 4% to $11.32 bil, falling short of estimates for $11.36 bil. Merck (MRK) sees full-year EPS of $3.35-$3.53, in line with views, but its revenue guidance fell short....
Merck Q4 Misses, But Cancer Deals Ignite Stock
at Investor's Business Daily - Wed Feb 05, 10:48AM CST
Big pharma Merck (MRK) missed sales estimates in its Q4 results and 2014 guidance Wednesday, but the stock hit a six-year high anyway after it announced a new set of deals in its cancer program. Merck said profit in the most recent quarter totaled 88...
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Positive Data on Novartis' Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 3:50PM CDT
Novartis announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Cancer Immunotherapy Race Stays Unpredictable
Amy Ho, The Motley Fool - Motley Fool - Fri Mar 07, 10:00AM CST
Cancer immunotherapy is a very hot field, and Bristol-Myers Squibb certainly took note, reallocating resources late last year to focus on the field, selling off its diabetes arm to AstraZeneca and ending new research in diabetes, hepatitis C and...
'Mad Money' Lightning Round: SunEdison Is Way Too Hot
at The Street - Fri Mar 07, 5:00AM CST
Cramer is avoiding GT Advanced Technologies and Incyte but wants Whole Foods for the long term.
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Business Wire - Fri Mar 07, 12:15AM CST
--Ruxolitinib is the first selective JAK1/JAK2 inhibitor to demonstrate efficacy in a Phase III trial for treating polycythemia vera
Jim Cramer's 'Mad Money' Recap: How to Value a Stock
at The Street - Thu Mar 06, 7:08PM CST
There are many ways to do so, and sticking to just one will cost you money, Cramer warns.
Incyte to Present at Upcoming Investor Conferences
Business Wire - Tue Feb 18, 3:10PM CST
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March:
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 4:05PM CST
Stock market correction, it's like we hardly even knew you! After dipping more than 100 points below its all-time closing high, the broad-based S&P 500 has now galloped higher in four of the past five trading sessions and is once again within...
The Hidden Gems in Gilead Sciences' Pipeline
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 1:30PM CST
When most biotech investors think about Gilead Sciences , they usually think of the company's portfolio of antiviral drugs and its newly approved potential blockbuster hepatitis C treatment, Sovaldi. Gilead's antiviral portfolio,...
Wider-than-Expected Q4 Loss at Incyte - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 12:10PM CST
Incyte reported a loss of 15 cents per share in the fourth quarter of 2013 wider than the Zacks Consensus Estimate of a loss of 9 cents.
Incyte Q4 swings to a loss
at Investor's Business Daily - Wed Feb 12, 5:43PM CST
The biotech reported a loss of 15 cents per share vs. a gain of 14 cents per share in the year-ago quarter. Analysts expected an 11-cent loss. Revenue fell 14.7% to $97.07 mil, falling short of views for $97.25 mil. Incyte (INCY) revenues from its...
Incyte's Q4 Loss Widens Despite Improved Jakafi Sales
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 12, 12:38PM CST
Oncology and inflammation-focused biopharmaceutical company Incyte reported its fourth-quarter results before the opening bell today. Incyte's results point toward growing sales of its lead drug, but also growing losses. For the quarter,...
Why Incyte (INCY) Is Up Today
at The Street - Wed Feb 12, 11:52AM CST
Incyte (INCY) rises to a nearly 14-year high of $69.98 as of 12:15 p.m. on Wednesday after the pharmaceutical company announced its fourth-quarter and full-year results. For the quarter and full year, both of which ended on Dec. 31, 2013, net product...
Today’s Top Biotech Stories: The Medicines Company, DaVita HealthCare Partners, and Incyte
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 7:45AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs
Business Wire - Wed Feb 12, 6:00AM CST
--Net product revenue guidance for 2014 in the range of $315 million to $335 million, reflecting continued growth in underlying demand
Merck Falling Earnings Hide Hidden Potential
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Sat Feb 08, 6:00AM CST
In this segment from Market Checkup , Motley Fool's health-care focused investing show, analysts David Williamson and Max Macaluso look at Merck's recent quarterly results. The Big Pharma posted declining revenue and net income, missing analyst...
5 Stocks Moving The Health Care Sector Upward
at The Street - Thu Feb 06, 11:03AM CST
TheStreet highlights 5 stocks pushing the health care sector higher today.
Merck soars on cancer deal
at Investor's Business Daily - Wed Feb 05, 5:56PM CST
The pharmaceutical giant's Q4 EPS rose 6% to 88 cents, in line with views. Sales fell 4% to $11.32 bil, falling short of estimates for $11.36 bil. Merck (MRK) sees full-year EPS of $3.35-$3.53, in line with views, but its revenue guidance fell short....
Merck Q4 Misses, But Cancer Deals Ignite Stock
at Investor's Business Daily - Wed Feb 05, 10:48AM CST
Big pharma Merck (MRK) missed sales estimates in its Q4 results and 2014 guidance Wednesday, but the stock hit a six-year high anyway after it announced a new set of deals in its cancer program. Merck said profit in the most recent quarter totaled 88...
